Access cutting-edge idh-mutant glioma treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access idh-mutant glioma specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related idh-mutant glioma treatment provided free
The objective of this study is to determine the safety and tolerability of vorasidenib in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib. The study will begin as a Phase Ib study to determine the RCD and then will transition to a Phase II study to assess the clinical efficacy of vorasidenib at the RCD in combination with TMZ. During the treatment period participants will have study visits on day 1 and 22 of each cycle, with additional v
Sponsor: Institut de Recherches Internationales Servier
Check if you qualify for this idh-mutant glioma clinical trial in Los Angeles, CA
If you're searching for idh-mutant glioma treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced idh-mutant glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.